Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
Author(s) -
William A. Freed-Pastor,
Hideaki Mizuno,
Xi Zhao,
Anita Langerød,
SungHwan Moon,
Ruth RodríguezBarrueco,
Anthony M. Barsotti,
Agustin Chicas,
Wencheng Li,
Alla Polotskaia,
Mina J. Bissell,
Timothy F. Osborne,
Bin Tian,
Scott Lowe,
José M. Silva,
AnneLise BørresenDale,
Arnold J. Levine,
Jill Bargonetti,
Carol Prives
Publication year - 2012
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2011.12.017
Subject(s) - biology , mutant , microbiology and biotechnology , mevalonate pathway , medicine , genetics , biosynthesis , gene
p53 is a frequent target for mutation in human tumors, and mutant p53 proteins can actively contribute to tumorigenesis. We employed a three-dimensional culture model in which nonmalignant breast epithelial cells form spheroids reminiscent of acinar structures found in vivo, whereas breast cancer cells display highly disorganized morphology. We found that mutant p53 depletion is sufficient to phenotypically revert breast cancer cells to a more acinar-like morphology. Genome-wide expression analysis identified the mevalonate pathway as significantly upregulated by mutant p53. Statins and sterol biosynthesis intermediates reveal that this pathway is both necessary and sufficient for the phenotypic effects of mutant p53 on breast tissue architecture. Mutant p53 associates with sterol gene promoters at least partly via SREBP transcription factors. Finally, p53 mutation correlates with highly expressed sterol biosynthesis genes in human breast tumors. These findings implicate the mevalonate pathway as a therapeutic target for tumors bearing mutations in p53.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom